Patents by Inventor Shilpak Chatterjee

Shilpak Chatterjee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD38-NAD+ REGULATED METABOLIC AXIS IN ANTI-TUMOR IMMUNOTHERAPY
    Publication number: 20240122986
    Abstract: The present disclosure provides methods of producing hybrid Th1/Th17 cells. Also provided herein are methods of treating cancer comprising targeting the CD38-mediated metabolic axis.
    Type: Application
    Filed: December 18, 2023
    Publication date: April 18, 2024
    Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventors: Shikhar MEHROTRA, Shilpak CHATTERJEE
  • CD38-NAD+ regulated metabolic axis in anti-tumor immunotherapy
    Patent number: 11883430
    Abstract: The present disclosure provides methods of producing hybrid Th1/Th17 cells. Also provided herein are methods of treating cancer comprising targeting the CD38-mediated metabolic axis.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: January 30, 2024
    Assignee: MUSC Foundation for Research Development
    Inventors: Shikhar Mehrotra, Shilpak Chatterjee
  • PROCESSES FOR GENERATING SUPERIOR ANTI-TUMOR T-CELL EFFECTOR AND MEMORY CELLS
    Publication number: 20230025360
    Abstract: The present invention relates to an adoptive T cell therapy using cells generated by genetically or biochemically reprogramming T cells to produce T memory stem cells (Tscm) that persist longer in vivo and are superior anti-tumor effector cells.
    Type: Application
    Filed: August 3, 2022
    Publication date: January 26, 2023
    Inventors: Shikhar Mehrotra, Pravin Kesarwani, Shilpak Chatterjee
  • CD38-NAD+ REGULATED METABOLIC AXIS IN ANTI-TUMOR IMMUNOTHERAPY
    Publication number: 20190255111
    Abstract: The present disclosure provides methods of producing hybrid Th1/Th17 cells. Also provided herein are methods of treating cancer comprising targeting the CD38-mediated metabolic axis.
    Type: Application
    Filed: November 8, 2017
    Publication date: August 22, 2019
    Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventors: Shikhar MEHROTRA, Shilpak CHATTERJEE
  • PROCESSES FOR GENERATING SUPERIOR ANTI-TUMOR T-CELL EFFECTOR AND MEMORY CELLS
    Publication number: 20190125796
    Abstract: The present invention relates to an adoptive T cell therapy using cells generated by genetically or biochemically reprogramming T cells to produce T memory stem cells (Tscm) that persist longer in vivo and are superior anti-tumor effector cells.
    Type: Application
    Filed: April 28, 2017
    Publication date: May 2, 2019
    Applicant: MUSC Foundation for Research Development
    Inventors: Shikhar Mehrotra, Michael I. Nishimura, Pravin Kesarwani, Shilpak Chatterjee